In October 2013, Amgen, a biotechnology pioneer since 1980 and one of the world's leading independent biopharmaceutical companies, and Astellas Pharma, a leading Tokyo-based global pharmaceutical company, together founded Amgen Astellas BioPharma with a mission to deliver breakthrough-science-based medicines and contribute to the creation of a healthy society. Since then, we have been tirelessly striving to address unmet medical needs of patients who need innovative medicines to fight disease.
Our aspirations evolved into Amgen Astellas BioPharma’s first MHLW approved product in January 2016. And the efforts continue to further enhance new therapeutic options for patients in Japan.
To fulfill our mission, Amgen Astellas BioPharma work in a spirit of one team to realize the following visions:
At Amgen Astellas BioPharma, we are committed to developing new ways to tackle disease. The future is one of crossing new scientific frontiers, doing what we can to serve patients and advance the practice of medicine in Japan.
General Manager and Representative
Amgen Astellas BioPharma K.K.